How does brenipatide compare to tirzepatide?

Both are dual GIP/GLP-1 agonists from Eli Lilly. Brenipatide has a longer half-life enabling once-monthly dosing (vs weekly for tirzepatide) and is being developed primarily for neuropsychiatric conditions (addiction, bipolar disorder) rather than obesity/diabetes. No head-to-head efficacy data exists yet.

Why is an obesity drug being tested for alcohol addiction?

GLP-1 and GIP receptors are expressed in brain reward circuits, not just the gut and pancreas. Preclinical research shows dual GIP/GLP-1 agonists attenuate alcohol-induced dopamine signaling and reduce voluntary alcohol consumption. Brenipatide targets the same reward pathways that drive both overeating and substance dependence.

When will brenipatide be available?

Brenipatide is still in clinical trials. Phase 3 studies for alcohol use disorder and bipolar disorder are underway. Phase 1 trials for obesity and metabolic disorders are earlier-stage. No approval date has been announced. It does not currently have FDA approval for any indication.

Brenipatide

A once-monthly dual GIP/GLP-1 receptor agonist from Eli Lilly, in Phase 3 trials for alcohol use disorder and bipolar disorder, with additional studies in obesity, asthma, and smoking cessation.

LimitedLimited Data

What is Brenipatide?

Brenipatide (LY3537031) is a dual GIP/GLP-1 receptor agonist under development by Eli Lilly. It belongs to the same drug class as tirzepatide (Mounjaro/Zepbound) but is engineered with a longer half-life that enables once-monthly subcutaneous dosing — compared to weekly injections for tirzepatide, semaglutide, and retatrutide. A key structural modification (Trp to alpha-methyl-tyrosine substitution) enhances its resistance to enzymatic degradation. What makes brenipatide unusual among incretin mimetics is its primary development focus: rather than leading with obesity or diabetes, Lilly is running Phase 3 trials in alcohol use disorder and bipolar disorder, targeting the dopamine reward pathways that GIP/GLP-1 signaling modulates.

Why People Talk About It

Once-monthly dosing (vs weekly for other GLP-1s)

Limited

Alcohol use disorder treatment

Limited

Bipolar disorder symptom management

Limited

Dopamine reward pathway modulation

Limited

Obesity and metabolic disorders

Limited

How It Works

Brenipatide activates the same two hormone receptors as tirzepatide (GIP and GLP-1), but with a much longer duration of action — lasting a month instead of a week. Beyond the metabolic effects on blood sugar and appetite, it also modulates dopamine reward signaling in the brain, which is why Lilly is studying it for addiction and psychiatric conditions.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

No published safety data yet — clinical trials are ongoingExpected GI side effects based on the GIP/GLP-1 drug class (nausea, vomiting, diarrhea)

Cautions

• Investigational drug — not FDA-approved for any indication
• No published efficacy or safety data from clinical trials
• Not available outside of clinical trial enrollment

What We Don't Know

All safety and efficacy data is currently unpublished. As an investigational drug, the risk profile is undefined. The once-monthly dosing raises questions about management of adverse effects, since the drug cannot be quickly discontinued if side effects occur.

Published Research

5 studies

Tirzepatide attenuates dopamine reward signaling and suppresses alcohol drinking and relapse-like behaviors in rodents.

Preclinical

Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review.

Systematic Review

Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights.

Review

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1).

Clinical Trial Registration

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Review

Mechanism of Action

Brenipatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Like tirzepatide, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Its distinguishing feature is a structural modification (Trp to alpha-methyl-tyrosine substitution) that confers resistance to enzymatic degradation, producing a half-life longer than tirzepatide or retatrutide and enabling once-monthly dosing. Beyond metabolic effects, GLP-1 receptor activation dampens reward signaling through alpha-MSH-driven GABAergic inhibition of the paraventricular nucleus to ventral tegmental area pathway and direct modulation of VTA dopaminergic neurons. GIP receptor activation promotes PI3K/AKT/mTOR-mediated synaptic plasticity, potentially enhancing top-down control over reward-seeking behavior. Preclinical data with the related dual agonist tirzepatide demonstrated attenuation of alcohol-induced dopamine signaling and dose-dependent reduction in voluntary alcohol consumption.

Evidence Snapshot

Overall Confidence15%

Human Clinical Evidence

None published. Phase 3 trials are underway for alcohol use disorder (RENEW-ALC-1, ~1,100 participants) and bipolar disorder. Phase 2 trials are running for asthma and smoking withdrawal. Phase 1 trials are active for cardiovascular, liver, and metabolic disorders including obesity. No efficacy or safety data from these trials has been published.

Animal / Preclinical

Indirect. No published preclinical data specific to brenipatide (LY3537031). Mechanistic support comes from studies of the related dual GIP/GLP-1 agonist tirzepatide, which attenuated alcohol-induced dopamine signaling and reduced voluntary alcohol consumption and relapse-like drinking in rodent models.

Mechanistic Rationale

Moderate. The dual GIP/GLP-1 mechanism is well-validated for metabolic indications by tirzepatide's clinical success. The extension to addiction and neuropsychiatric conditions is supported by growing evidence that GLP-1 receptors modulate dopamine reward circuits, though this therapeutic application remains unproven in humans.

Forms & Administration

Brenipatide is administered via subcutaneous injection once monthly. It is currently only available through clinical trial enrollment and is not commercially available. All investigational peptides should only be used within the context of approved clinical trials.

Use Cases & Evidence Levels

Once-monthly dosing (vs weekly for other GLP-1s)

Limited15%

Alcohol use disorder treatment

Limited15%

Bipolar disorder symptom management

Limited15%

Dopamine reward pathway modulation

Limited15%

Obesity and metabolic disorders

Limited15%

Safety Profile

Safety Information

Common Side Effects

No published safety data yet — clinical trials are ongoingExpected GI side effects based on the GIP/GLP-1 drug class (nausea, vomiting, diarrhea)

Cautions

• Investigational drug — not FDA-approved for any indication
• No published efficacy or safety data from clinical trials
• Not available outside of clinical trial enrollment

What We Don't Know

Published Research

5 studies

Tirzepatide attenuates dopamine reward signaling and suppresses alcohol drinking and relapse-like behaviors in rodents.

Preclinical

Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review.

Systematic Review

Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights.

Review

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1).

Clinical Trial Registration

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Review

Research Insights

GLP-1 Drugs and Addiction: Can Ozempic Curb Alcohol, Opioids, and More?

A landmark study of 606,000 veterans found GLP-1 drugs reduced new substance use disorders by 14-25% and overdose deaths by 50%. From alcohol to opioids to cannabis, the reward-pathway science is catching up to what patients have been reporting for years.

Related Peptides

Tirzepatide

StrongBeginner

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

Semaglutide

StrongBeginner

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.

Retatrutide

Emerging

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.